FUJIFILM Corporation plans to open a new large scale cell culture manufacturing site for biopharmaceuticals with an investment of more than US$ 2 billion. The new site will be located adjacent to the existing site in USA.
The new production facility will advance the growth of its biopharmaceutical Contract Development and Manufacturing business (CDMO). In addition, the investment made in this new site helps in fulfilling the unmet medical needs with the manufacturing of new drugs.
The new production facility will be situated adjacent to the existing site and offers commercial scale automated fill-finish and assembly, packaging and labelling services other than drug manufacturing substances.
The facility offers 8 x 20,000L bioreactors to expand with the addition of 24 x 20,000L bioreactorsfor large-scale cell culture manufacturing.
The production facility is expected to start its operation in the spring of 2025.